This study of plasma EBV DNA in patients with RM-NPC who are receiving anti-PD-1 monotherapy suggests that plasma EBV DNA could be a useful biomarker for outcomes and monitoring disease progression. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.